3Sbio
HKEX:01530Shenyang, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileOverview
Leading Chinese biopharma company developing innovative biologics for oncology, immunology, nephrology, and dermatology with full-cycle R&D capabilities.
OncologyImmunologyNephrologyDermatology
Technology Platform
Integrated biologics platform with capabilities in recombinant protein engineering, monoclonal antibody development, and full-cycle drug development from research to commercialization.
Opportunities
Significant growth potential in China's expanding biologics market, international expansion of both therapeutic products and CDMO services, and leveraging established commercial infrastructure for new product launches.
Risk Factors
Increasing competition in Chinese biopharma sector, pricing pressures in domestic market, regulatory challenges for international expansion, and pipeline dependency on successful clinical outcomes.
Competitive Landscape
Competes with other major Chinese biopharma companies like Innovent Biologics, Hengrui Medicine, and BeiGene, differentiated by established commercial scale, profitable operations, and diversified business model combining therapeutics with CDMO services.